

Chinese Herbal Medicines for Sepsis Treatment

Subjects: **Pharmacology & Pharmacy**

Contributor: Chen Cheng

Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection; the pathophysiology of sepsis is complex. The incidence of sepsis is steadily increasing, with worldwide mortality ranging between 30% and 50%. Current treatment approaches mainly rely on the timely and appropriate administration of antimicrobials and supportive therapies, but the search for pharmacotherapies modulating the host response has been unsuccessful. Chinese herbal medicines, i.e., Chinese patent medicines, Chinese herbal prescriptions, and single Chinese herbs, play an important role in the treatment of sepsis through multicomponent, multipathway, and multitargeting abilities and have been officially recommended for the management of COVID-19.

Chinese herbal medicines

sepsis

1. Introduction

Based on the characteristics of emergency medicine in China, the Preventing Sepsis Campaign in China (PSCC) was initiated in May 2018 ^[1]. It was advocated by experts that the prevention, diagnosis, and treatment of sepsis should be performed as early as possible to decrease morbidity and mortality, and the principle of the prevention of sepsis was introduced to prevent its occurrence. Several Chinese treatment guidelines for sepsis management and expert consensus—e.g., the Chinese guidelines for the emergency management of sepsis and septic shock 2018, the clinical practice guidelines on traditional Chinese medicine therapy alone or combined with antibiotics for sepsis, and the Chinese emergency medicine expert consensus on the diagnosis and treatment of sepsis complicated by disseminated intravascular coagulation—have been successively released for the management of sepsis ^{[2][1][3]}. In these treatment guidelines and expert agreements, CHMs are recommended as add-on therapies to complement the conventional treatment of sepsis, e.g., a XueBiJing injection (XBJ) for sepsis, a ShenFu injection (SF) for septic shock, the ShengMai formula (SMF) for sepsis with the qi and yin exhaustion pattern, the Xuanbai Chengqi decoction (XBCQ) for sepsis with acute respiratory distress syndrome (ARDS), the Qingwen Baidu decoction (QWBD) for sepsis with the internal exuberance of toxins and heat pattern, etc. ^[4]. The diagnosis and treatment protocol for COVID-19 (the revised eighth version) released by China's National Health Commission also recommends the use of CHM in accordance with different degrees of severity of COVID-19 ^[5]. XueBiJing, ShenFu, and ShengMai injections are typical herbal injections officially recommended for the management of COVID-19 when patients with a severe case of the disease develop SIRS and/or MODS ^[5].

2. Chinese Patent Medicines - XueBiJing Injection

The XueBiJing injection (XBJ), derived from the Xuefu Zhuyu decoction, is an injectable licensed in China since 2004 for sepsis and MODS, with a National Medical Products Administration (NMPA) drug ratification number of GuoYaoZhunZi-Z20040033. It is exclusively manufactured by Tianjin Chasesun Pharmaceutical (Tianjin, China). The herbal injection is prepared from a combination of *Carthamus tinctorius* flower (Honghua in Chinese), *Paeonia lactiflora* root (Chishao), *Salvia miltiorrhiza* root (Danshen), *Ligusticum chuanxiong* rhizome (Chuanxiong), and *Angelica sinensis* root (Danggui). Several meta-analyses have suggested that the addition of XBJ to routine sepsis care could further reduce the 28-day mortality of patients and incidence of complications, and improve patient prognosis [6][7][8][9][10]. The 28-day mortality is the primary clinical outcome of sepsis care. In a prospective, randomized controlled trial in 710 patients with severe community-acquired pneumonia, adding XBJ to the conventional treatment reduced the 28-day mortality from 24.6% (conventional treatment) to 15.9% (conventional treatment + XBJ), increased the percentage of patients with improved pneumonia severity indices from 46.3% to 60.8%, and improved their Sequential Organ Failure Assessment (SOFA) scores from 4.44 to 3.65 and Acute Physiology and Chronic Health Evaluation (APACHE) II scores from 11.12 to 9.19 ($p < 0.01$ for all) [11]. In a single-center, randomized, double-blinded, prospective trial in 60 patients with severe COVID-19, significant improvements in the rates of septic shock and mechanical ventilation, as well as the proportion of patients severely affected, the duration until the main clinical symptoms improved ($p < 0.05$ for all), and the lengths of ICU hospitalization ($p < 0.01$), were observed for the XBJ group (routine medication + XBJ) after 14 days of treatment, compared with the control group (routine medication + saline) [12]. A large-scale survey involving 31,913 hospitalized patients indicated that the incidence of adverse drug reactions (ADRs) to XBJ was at the occasional level (0.3%); most of these reactions were mild or nonserious [13]. Another analysis of data from the Hospital Information System indicated that the ADRs to XBJ were mainly correlated with age, dosage, vehicle type, and drug combination [14]. A recent investigation by our group suggested that the herbal compounds in XBJ have a low potential to participate in therapeutic pharmacokinetic interactions with antibiotics when coadministered with XBJ in sepsis care [15].

Many pharmacological studies have suggested that the antiseptic action of XBJ is correlated with the modulation of the host response, i.e., inhibiting the uncontrolled release of inflammatory mediators, relieving an early overabundant innate immune response and potentially cumulative immunosuppression, attenuating crosstalk between inflammation and coagulation, protecting endothelial cells, and maintaining the physiologic functions of vital organs [16][17][18][19]. Zhou et al. identified four biological functional actions of XBJ in sepsis: the regulation of inflammation, immune activity, cell apoptosis, and coagulation [20]. XBJ can significantly alleviate liver injury in cecal ligation and puncture (CLP) rats via downregulating tumor necrosis factor- α (TNF- α) and interleukin 6 (IL-6) expression while upregulating IL-10 expression and promoting the suppression of cytokine signaling 1 (SOCS1) expression [21]. XBJ played a protective role in methicillin-resistant *Staphylococcus aureus* (MRSA)-challenged mice by downregulating the inflammatory response (IL-6, TNF- α , IL-1 β , and IL-12) and signaling pathways (NF- κ B, MAPK, and PI3K/Akt) activated by Pam3CSK4 (a synthetic tripalmitoylated lipopeptide mimicking bacterial lipoproteins) [22]. A study based on a sepsis rat model indicated that adding XBJ to antibiotics could improve renal perfusion and oxygenation and suppress renal inflammation, as well as ameliorate kidney dysfunction [23]. A rat- and cell-based study indicated that XBJ may improve pulmonary vascular barrier function by upregulating claudin-5

expression in a rat model with acute lung injury (ALuI) [24]. A GC/MS-based metabonomics approach revealed that XBJ reduced multiorgan dysfunctions in septic rats and increased their survival rate: serum biochemistry indicators including blood urea nitrogen (BUN), creatinine (Cr), alanine aminotransferase (ALT), and aspartate aminotransferase (AST); cytokines (TNF- α and IL-6); and morphologic changes all decreased [25].

XBJ may improve the clinical symptoms and alleviate the disease severity of COVID-19. By using network pharmacology and molecular docking analysis approaches, the active ingredients, potential molecular targets, and mechanisms of XBJ have been investigated [26][27]. Similarly, to explore the multicomponent, multipathway, and multitarget mechanisms of XBJ in sepsis, a drug–target–pathway network and a drug–ingredients–targets–disease network of XBJ were constructed by Zuo et al. and Feng et al., respectively, to identify major active ingredients, targets, and signaling pathways [28][29].

XBJ is a chemically complex herbal injection; more than 100 constituents, including Honghua flavonoids, Chishao monoterpene glycosides, Danshen catechols, Chuanxiong/Danggui phthalides, and other types of constituents, have been detected and characterized in XBJ [15][30]. Additionally, several analytical assays have been developed for the quantification of the multiple constituents in XBJ [30][31][32][33][34]. Based on the comprehensive chemical composition analysis of XBJ, the human pharmacokinetics of XBJ (by dosing with labeled doses) were systematically investigated by Li et al., and the disposition of major circulating XBJ compounds was well characterized with supportive rat studies and in vitro metabolism and transport studies [15][35][36][37]. Accordingly, 13 major circulating XBJ compounds originating from the five component herbs were identified, i.e., hydroxysafflor yellow A from Honghua; paeoniflorin, oxypaeoniflorin, and albiflorin from Chishao; senkyunolide I, senkyunolide I-7-O- β -glucuronide, senkyunolide G, and ferulic acid from Chuanxiong and Danggui; tanshinol, 3-O-methyltanshinol, protocatechuic acid, salvianolic acid B, and 3-O-methylsalvianolic acid B from Danshen. Among these compounds, senkyunolide I-7-O- β -glucuronide, 3-O-methyltanshinol, protocatechuic acid, and 3-O-methylsalvianolic acid B are the in vivo metabolites of senkyunolide I, tanshinol, protocatechuic aldehyde, and salvianolic acid B, respectively; the unchanged compound protocatechuic aldehyde could not be detected in human plasma samples [15][35][36][37]. Several other research groups also measured circulating herbal compounds in their unchanged forms in rats receiving XueBiJing based on developed bioanalytical assays [38][39][40][41]. Zuo et al. investigated the tissue distributions of several bioactive compounds in rats after they intravenously received XBJ, and the levels of exposure to four compounds (i.e., hydroxysafflor yellow A, paeoniflorin, ferulic acid, and benzoylpaeoniflorin) were found to be high in the kidneys, liver, stomach, and intestines [38]. Hydroxysafflor yellow A, despite its poor membrane permeability, could partly cross the damaged blood–brain barrier in patients with traumatic brain injury after the intravenous administration of XBJ [42].

The antisepsis-related activities—i.e., anti-inflammatory, anticoagulant, endothelium-protective, immune-regulatory, antioxidant, and organ-protective activities—of the aforementioned unchanged circulating compounds from XBJ, based on animal or cellular studies, have been widely reported [43][44][45][46][47][48][49][50]. However, the experimental doses or concentrations of the test XBJ compounds were poorly related to their systemic exposure levels. Therefore, the antisepsis-related activities of the major pharmacokinetically identified circulating compounds were systematically evaluated at the concentrations of their systemic exposure levels after dosing XBJ in in vitro studies

and for individual doses of XBJ in a CLP rat study. Finally, six XBJ compounds (hydroxysafflor yellow A, paeoniflorin, oxypaeoniflorin, albiflorin, tanshinol, and senkyunolide I; **Figure 1**) were identified to be the material basis of XBJ: the survival rate of CLP rats receiving the intravenous injection of the combination of the six XBJ compounds proved to be comparable to that of CLP rats receiving XBJ. The survival rates of both groups were significantly lower than that of CLP control rats receiving 0.9% saline ($p < 0.05$; pending publication). **Table 1** lists some potential target pathways of the bioavailable and bioactive XBJ compounds.




Figure 1. Chemical structures of bioactive and bioavailable herbal compounds from antiseptic Chinese herbal medicines.

Table 1. Chemical compositions, pharmacological actions, bioactive compounds, and mechanisms of action of representative antiseptic Chinese herbal medicines.

Prescription	Component Herbs	Chemical Composition	Pharmacological Actions	Bioactive and Bioavailable Compounds	Potential Target Pathway	Potential DDI Target	References
XueBiJing injection	<i>Carthamus tinctorius</i> flower (Honghua in Chinese), <i>Paeonia lactiflora</i> root (Chishao), <i>Ligusticum chuanxiong</i> rhizome (Chuanxiong), <i>Angelica sinensis</i> root (Danggui), and <i>Salvia miltiorrhiza</i> root (Danshen)	Flavonoids, monoterpene glycosides, catechols, phthalides, organic acids, etc.	Exhibit anti-inflammatory, anticoagulant, endothelium-protective, immunoregulatory, antioxidant, and organ-protective activities; inhibit ox-LDL-induced apoptosis; improve microcirculation and myocardial ischemia/reperfusion injury	Hydroxysafflor yellow A	TLR4/NF-κB; NLRP3; Rac1/Akt; NF-κB/ICAM-1	—	[45] [47] [48] [51]
				Paeoniflorin Oxypaeoniflorin Albiflorin	SIRT1; IRAK1-NF-κB; IκB; PI3K/Akt; TLR2; Sirt1/Foxo1	—	[19] [43] [46] [52] [53] [54]
				Senkyunolide I	p-Erk1/2; Nrf2/HO-1; Caspase 3; MAPK; TLRs	As victim: UGT2B15	[15] [19] [50] [55]
				Tanshinol	cAMP-PKA	As victim: OAT1/2	[15] [44]
ShenFu injection	<i>Panax ginseng</i> steamed root (Hongshen) and processed <i>Aconitum camichaelii</i> root (Fuzi)	Ginsenosides, aconitum alkaloids, organic acids, etc.	Regulate oxidative stress and inflammatory responses, inhibit HMGB1-mediated severe inflammatory response, restore endothelial integrity, attenuate the proinflammatory response, enhance innate immunity, preserve adaptive immunity, alleviate neuropathic pain	Ginsenosides Rb ₁ , Rc, Rb ₂ , Rf, Rd, Rg ₁ , etc.	TLR4; PXR/NF-κB; TLRs/IRAK-1; TBK-1/IκB kinase ε/IRF-3; p38/ATF-2	As substrate: OATP1B3 (for Ginsenosides Rg ₁ , Rf) As perpetrator: OATP1B1/1B3 (for Ginsenosides Rb ₁ , Rc, Rb ₂ , Rd)	[56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68]
				Benzoylmesaconine Fuzilene Mesaconine Neoline Songorine	TLR4/NF-κB; Nrf2	As victim: P-gp (for benzoylmesaconine)	[69] [70] [71] [72]
ShengMai formula	<i>Panax ginseng</i> root (Renshen), <i>Ophiopogon japonicus</i> root (Maidong), and <i>Schisandra chinensis</i> fruit (Wuweizi)	Ginsenosides, lignans, steroidal saponins, and homoisoflavanones	Exhibit anti-inflammatory or antioxidant, hepatoprotective activities	Ginsenosides Rb ₁ , Rb ₂ , Rc, Rd, Re, Rg ₁ , Rh ₁ , Compound K, Rf, and Rg ₂	TLR4; PXR/NF-κB; TLRs/IRAK-1; TBK-1/IκB kinase ε/IRF-3; p38/ATF-2	As substrate: OATP1B1/1B3 (for Ginsenoside Rg ₂) OATP1B3 (for Ginsenosides Rg ₁ , Rf, Re) As perpetrator: OATP1B1/1B3 (for Ginsenosides Rb ₁ , Rc, Rb ₂ , Rd) NTCP (for Rg1) CYP3A (for Rd)	[56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [73] [74] [75] [76]
				Ophiopogonin D Ophiopogonin D'	PPARα; NF-κB/IκBα; SIRT1; TLR4;	As perpetrator: CYP3A4, 2C9, and	[67] [76] [77] [78] [79] [80]

Prescription	Component Herbs	Chemical Composition	Pharmacological Actions	Bioactive and Bioavailable Compounds	Potential Target Pathway	Potential DDI Target	References
Qingwen Baidu decoction	<i>Rehmannia glutinosa</i> root (Dihuang), <i>Rhinoceros unicornis</i> horn (Xijiao), <i>Coptidis chinensis</i> rhizome (Huanglian), <i>Gardenia jasminoides</i> fruit (Zhizi), <i>Platycodon grandiflorum</i> root (Jiegeng), <i>Scutellaria baicalensis</i> root (Huangqin), <i>Anemarrhena asphodeloides</i> rhizome (Zhimu), <i>Paeonia lactiflora</i> root (Chishao), <i>Scrophularia ningpoensis</i> root	Alkaloids, iridoids, flavonoids, etc.	Reduce LPS-induced intestinal damage; treat inflammation; alleviate LPS-induced acute kidney injury; alleviate liver injury in sepsis; exhibit anti-inflammatory, antioxidant, and cardioprotective effects	Ruscogenin	TLR4/NF-κB/MyD88	2E1 (for Ophiopogonin D) UGT1A6/1A8 (for Ophiopogonin D) UGT1A6/1A10 (for Ophiopogonin D') NTCP (for Ophiopogonin D') CYP3A (for Ophiopogonin D) As victim: OATP1B1/1B3 (for Ophiopogonin D)	[81]
				Schisandrol A Schisandrol B Schizandrin A Schizandrin B Deoxyschisandrin	iNOS; COX-2; PGE2; MAPK; TLR4/NF-κB/MyD88	As perpetrator: NTCP (for Schizandrin A)	[75][82][83][84][85]
				Berberine	TLRs; NF-κB; STAT3; Wnt/β-catenin; PI3K/Akt; MAPK/JNK/p38/ERK	As perpetrator: CYP3A4, CYP2D6 As victim: P-gp	[86][87][88][89][90][91][92]
				Geniposide Genipin	NF-κB; MAPK; PPARγ; AMPK; NLRP3; AKT-mTOR	—	[93][94][95][96][97][98]
				Baicalin	iNOS; COX-2; NF-κB; HMGB1	As perpetrator: CYP1A2/3A/2E1, OATP1B1, P-gp	[99][100][101][102][103]
				Wogonoside Wogonin	TLR4; NF-κB; Nrf2; NLRP3	As perpetrator: CYP1A2 (for Wogonin)	[104][105][106][107][108]

3. Chinese Herbal Prescriptions-ShengMai Formula

The ShengMai formula (SMF), which was first recorded in Yi Xue Yuan Li, consists of *P. ginseng* root (Renshen), *Ophiopogon japonicus* root (Maidong), and *Schisandra chinensis* fruit (Wuweizi) with a dosage proportion of 5:3:1.5. It is normally prepared as ShengMai powder (SMP; or ShengMai san, SMS), ShengMai yin (SMY), ShengMai injection (SMI), etc., for clinical use. SMF is a classic tonic prescription for the treatment of tuberculosis, chronic bronchitis, cough due to neurasthenia, and heart failure [127]. SMI, an intravenous dosage form of SMF, is used to treat acute myocardial infarction, cardiogenic shock, toxic shock, hemorrhagic shock, coronary heart disease, endocrine disorders, and other diseases due to a deficiency of qi and yin, with low toxicity [128][129]. SMI is highly recommended for use in combination with antibiotics for community-acquired pneumonia in clinical guidelines [2]. A meta-analysis including 17 randomized controlled trials (RCTs) and 860 patients with septic shock

and a diagnostic fragment-ion-based extension strategy, Zheng et al. detected and identified more than 30 ginsenosides and 20 lignans from SMI [135]. Zhao et al. identified or partially characterized 87 herbal compounds in SMI and selected 6 bioactive constituents (four ginsenosides (i.e., Rg₁, Re, Rb₁, and Rd) and 2 lignans (i.e., schisandrol A and schisandrol B) with high content levels as quality markers (Q-markers). The total content range for these selected Q-markers in 10 batches of SMI was 13.8–22.5 mg/mL [136]. Wu et al. identified 92 compounds (i.e., 49 ginsenosides, 31 lignans, 5 steroidal saponins, and 7 homoisoflavanones) in SMP and discovered a class of 25-hydroxyginsenosides for the first time [137]. In a study by Cheng et al., 10 compounds (the ginsenosides Rb₁, Rb₂, Rc, Rd, Re, Rg₁, and Rh₁; compound K; ophiopogonin D; and schisandrol A) were measured in SMP, and the contents of these herbal constituents were found to vary by up to several hundredfolds among five pharmaceutical manufacturers [138]. In their study, Zheng et al. selected eight compounds (the ginsenosides Rf, Rb₁, Rg₂, and Rb₂; schisandrol A; schisandrol B; methylophiopogonanone A; and schisandrin B) as Q-markers to evaluate the batch-to-batch consistency of SMF; ginsenoside Rb₁, ranging from 2046.1 µg/g (1.84 µmol/g) to 5975.8 µg/g (5.39 µmol/g), was found to be the dominant component in SMF, followed by ginsenoside Rg₂ (838.3–2091.64 µg/g; 1.07–2.66 µmol/g) and ginsenoside Rb₂ (567.2–1989.9 µg/g; 0.53–1.84 µmol/g). The batch-to-batch chemical variation among 10 batches of SMF ranged from 27.9% (for ginsenoside Rf) to 113.95% (for schisandrol B) [139]. Li et al. established a seven-marker-based quality standard to quantify seven ginsenosides (i.e., the ginsenosides Rf, Rd, Rc, Re, Rb₁, Rb₂, and Rg₁) in SMI, which was then used to evaluate the quality consistency of 22 batches of SMI [140]. Li et al. detected 62 compounds in SMI and established a quantitative assay for the determination of 21 main components, including 14 saponins, 6 lignans, and 1 pyranoglucoside, and found the contents of these 21 components to vary widely amongst 10 batches [141].

Lu et al. established a TCM-components-core targets-key pathway network platform to investigate the mechanism of SMI's effects in sepsis. SMI was found to mainly affect several signaling pathways, suggesting that SMI could regulate immunity, inflammation, apoptosis, and energy metabolism for the protection of multiple organs. Gene ontology (GO) enrichment analysis further indicated that the bioactive SMI constituents altered the pathophysiology of sepsis through the regulation of various biological processes [142]. SMP protected against I/R-induced blood-brain barrier (BBB) dysfunction by significantly upregulating ZO-1 and claudin-5 under oxygen-glucose deprivation/reoxygenation (OGD/R), as well as reducing matrix metalloproteinase 2/9 (MMP-2/9) levels and the phosphorylation of myosin light-chain (MLC) through the ROCK/cofilin signaling pathway [143].

Zhan et al. developed and validated a sensitive LC-MS/MS method for the simultaneous quantification of 11 SMI compounds in rat serum and applied it to a pharmacokinetic study in rats after a single intravenous administration of SMI. The 11 constituents were ppt-type ginsenosides (i.e., the ginsenosides Rg₁, Re, Rf, and Rg₂), ppd-type ginsenosides (i.e., the ginsenosides Rb₁, Rd, and Rc), ophiopogonin (ophiopogonin D), and lignans (i.e., schisandrol A, schisandrol B, and schisandrin B) [144][145]. A total of 30 compounds (23 prototype components and 7 metabolites) were detected and characterized in the plasma of rats after they received SMS (8 g/kg) [146][147]. Further, ppt-type ginsenosides were eliminated rapidly through urinary, biliary, and fecal excretions (plasma $t_{1/2\alpha}$, 0.60–0.82 h; MRT, 0.22–0.46 h), whereas the ppd-type ginsenosides Rb₁, Rd, and Rc exhibited slow elimination through biliary and urinary excretions (MRT, 23.0–28.6 h). Ophiopogonin D was mainly excreted in bile in the metabolized forms. Schisandrol A, schisandrol B, and schisandrin B, with low contents in SMI, were found to be eliminated quickly (plasma $t_{1/2\alpha}$, 0.51–1.98 h; MRT, 0.51–2.50 h) and accumulated in these tissues. Lignans were mainly excreted in their metabolized form, as indicated by the very low biliary, urinary, and fecal excretion of the unchanged forms [144][145]. SMI, within the concentration range of 30% (volume percentage), showed an inhibitory effect on the activities of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4, with IC₅₀ values of 6.12%, 2.72%, 10.00–30.00%, 14.31%, 12.96%, 12.26%, and 3.72%, respectively, and had an inhibitory effect on the activities of the transporters MDR1, BCRP, and organic anion transporting polypeptide (OATP)1B1, with IC₅₀ values of 0.15%, 0.75%, and 2.03%, respectively. This suggested a high risk of drug interactions of SMI when clinically combined with the use of the transporters MDR1 and BCRP substrate [148]. SMS selectively suppressed intestinal, but not hepatic, nifedipine oxidation (a CYP3A marker reaction) activity in a dose- and time-dependent manner. Three-week SMS treatment decreased the maximal velocity of intestinal nifedipine oxidation by 50%, while the CYP3A protein level remained unchanged; among the SMS component herbs, the decoction of *Ophiopogonis Radix* decreased the intestinal nifedipine oxidation activity [149]. Based on an inhibition kinetic investigation of various UGT isoforms, ophiopogonin D was found to noncompetitively inhibit UGT1A6 (K_i , 20.6 $\mu\text{mol/L}$) and competitively inhibit UGT1A8 (40.1 $\mu\text{mol/L}$); ophiopogonin D' noncompetitively inhibited UGT1A6 (5.3 $\mu\text{mol/L}$) and UGT1A10 (9.0 $\mu\text{mol/L}$); and ruscorectal competitively inhibited UGT1A4 (0.02 $\mu\text{mol/L}$) [81]. The ginsenoside Rg₁, ophiopogon D', and schisandrin A are potential inhibitors of sodium taurocholate co-transporting polypeptide (NTCP) and probably interact with NTCP-modulating clinical drugs. The ginsenoside Re and schisandrin B are potential NTCP substrates, and their NTCP-mediated uptake could be inhibited by other ingredients in SMF [75]. The ginsenosides Rb₂, Rc, Rg₂, Rg₃, Rd, and Rb₁ are P-gp substrates, and *Schisandra Lignans* extract (SLE) was found to significantly enhance the uptake and inhibit the efflux ratio of the ginsenosides

Rb₂, Rc, Rg₂, Rg₃, Rd, and Rb₁ in Caco-2 and L-MDR1 cells. Additionally, a rat study showed that a single dose and multiple doses of SLE at 500 mg/kg could significantly increase the AUC_{0–∞} of Rb₂, Rc, and Rd without affecting the $t_{1/2}$ ^[150]. The chemical structures of the major circulating SM compounds are shown in **Figure 1**, and their potential action target pathways are summarized in **Table 1**.

References

1. Yu, X.-Z.; Yao, Y.-M.; Zhou, R.-B. Chinese Guidelines for Emergency Management of Sepsis and Septic Shock 2018. *J. Clin. Emerg.* 2018, 38, 741–756.
2. Zhao, G.-Z.; Chen, R.-B.; Li, B.; Guo, Y.-H.; Xie, Y.-M.; Liao, X.; Yang, Y.-F.; Chen, T.-F.; Di, H.-R.; Shao, F.; et al. Clinical practice guideline on traditional Chinese medicine therapy alone or combined with antibiotics for sepsis. *Ann. Transl. Med.* 2018, 43, 4776–4881.
3. Wang, L.-J.; Chia, Y.-F. Chinese Emergency Medicine Expert Consensus on Diagnosis and Treatment of Sepsis Complicated with Disseminated Intravascular Coagulation. *Chin. Crit. Care Med.* 2017, 29, 577–580.
4. Wang, Z.; Yu, X.; Chen, Y.; Lv, C.; Zhao, X. Chinese expert consensus on early prevention and intervention of sepsis. *Asian Pac. J. Trop. Med.* 2020, 13, 335–349.
5. Chinese National Health Commission and Chinese State Administration of Traditional Chinese Medicine. Diagnosis and Treatment of Adults with Coronavirus Disease 2019 (COVID-19) (The Revised Eighth Version). 2021. Available online: <http://www.gov.cn/zhengce/zhengceku/2021-04/15/5599795/files/e9ce837932e6434db998bdbbc5d36d32.pdf> (accessed on 28 August 2021).
6. Li, C.; Wang, P.; Zhang, L.; Li, M.; Lei, X.; Liu, S.; Feng, Z.; Yao, Y.; Chang, B.; Liu, B.; et al. Efficacy and safety of Xuebijing injection (a Chinese patent) for sepsis: A meta-analysis of randomized controlled trials. *J. Ethnopharmacol.* 2018, 224, 512–521.
7. Chen, G.; Gao, Y.; Jiang, Y.; Yang, F.; Li, S.; Tan, D.; Ma, Q. Efficacy and Safety of Xuebijing Injection Combined with Ulinastatin as Adjunctive Therapy on Sepsis: A Systematic Review and Meta-Analysis. *Front. Pharmacol.* 2018, 9, 743.
8. Gao, J.; Kong, L.; Liu, S.; Feng, Z.; Shen, H.; Liu, Q. A prospective multicenter clinical study of Xuebijing injection in the treatment of sepsis and multiple organ dysfunction syndrome. *Chin. Crit. Care Med.* 2015, 27, 465–470.
9. Chen, Y.-X.; Li, C.-S. The Effectiveness of XueBiJing Injection in Therapy of Sepsis: A Multicenter Clinical Study. *China J. Emerg. Med.* 2013, 22, 130–135.
10. Wu, Y.; Zhang, J.; Qi, L. Clinical efficacy and safety of Xuebijing injection on sepsis: A Meta-analysis. *Chin. Crit. Care Med.* 2020, 32, 691–695.

11. Song, Y.; Yao, C.; Yao, Y.; Han, H.; Zhao, X.; Yu, K.; Liu, L.; Xu, Y.; Liu, Z.; Zhou, Q.; et al. XueBiJing Injection Versus Placebo for Critically Ill Patients with Severe Community-Acquired Pneumonia. *Crit. Care Med.* 2019, 47, e735–e743.
12. Luo, Z.; Chen, W.; Xiang, M.; Wang, H.; Xiao, W.; Xu, C.; Li, Y.; Min, J.; Tu, Q. The preventive effect of Xuebijing injection against cytokine storm for severe patients with COVID-19: A prospective randomized controlled trial. *Eur. J. Integr. Med.* 2021, 42, 101305.
13. Zheng, R.; Wang, H.; Liu, Z.; Wang, X.; Li, J.; Lei, X.; Fan, Y.; Liu, S.; Feng, Z.; Shang, H. A real-world study on adverse drug reactions to Xuebijing injection: Hospital intensive monitoring based on 93 hospitals (31,913 cases). *Ann. Transl. Med.* 2019, 7, 117.
14. Wang, C.; Shi, Q.-P.; Ding, F.; Jiang, X.-D.; Tang, W.; Yu, M.-L.; Cheng, J.-Q. Reevaluation of the post-marketing safety of Xuebijing injection based on real-world and evidence-based evaluations. *Biomed. Pharmacother.* 2019, 109, 1523–1531.
15. Li, J.; Olaleye, O.E.; Yu, X.; Jia, W.; Yang, J.; Lu, C.; Liu, S.; Yu, J.; Duan, X.; Wang, Y.; et al. High degree of pharmacokinetic compatibility exists between the five-herb medicine XueBiJing and antibiotics comedicated in sepsis care. *Acta Pharm. Sin. B* 2019, 9, 1035–1049.
16. Zuo, L.; Zhou, L.; Xu, T.; Li, Z.; Liu, L.; Shi, Y.; Kang, J.; Gao, G.; Du, S.; Sun, Z.; et al. Antiseptic Activity of Ethnomedicinal Xuebijing Revealed by the Metabolomics Analysis Using UHPLC-Q-Orbitrap HRMS. *Front. Pharmacol.* 2018, 9, 300.
17. Xu, T.; Zhou, L.; Shi, Y.; Liu, L.; Zuo, L.; Jia, Q.; Du, S.; Kang, J.; Zhang, X.; Sun, Z. Metabolomics approach in lung tissue of septic rats and the interventional effects of Xuebijing injection using UHPLC-Q-Orbitrap-HRMS. *J. Biochem.* 2018, 164, 427–435.
18. Chen, X.; Feng, Y.; Shen, X.; Pan, G.; Fan, G.; Gao, X.; Han, J.; Zhu, Y. Anti-sepsis protection of Xuebijing injection is mediated by differential regulation of pro- and anti-inflammatory Th17 and T regulatory cells in a murine model of polymicrobial sepsis. *J. Ethnopharmacol.* 2018, 211, 358–365.
19. Jiang, M.; Zhou, M.; Han, Y.; Xing, L.; Zhao, H.; Dong, L.; Bai, G.; Luo, G. Identification of NF- κ B Inhibitors in Xuebijing injection for sepsis treatment based on bioactivity-integrated UPLC-Q/TOF. *J. Ethnopharmacol.* 2013, 147, 426–433.
20. Zhou, W.; Lai, X.; Wang, X.; Yao, X.; Wang, W.; Li, S. Network pharmacology to explore the anti-inflammatory mechanism of Xuebijing in the treatment of sepsis. *Phytomedicine* 2021, 85, 153543.
21. Li, A.; Li, J.; Bao, Y.; Yuan, D.; Huang, Z. Xuebijing injection alleviates cytokine-induced inflammatory liver injury in CLP-induced septic rats through induction of suppressor of cytokine signaling 1. *Exp. Ther. Med.* 2016, 12, 1531–1536.

22. Li, T.; Qian, Y.; Miao, Z.; Zheng, P.; Shi, T.; Jiang, X.; Pan, L.; Qian, F.; Yang, G.; An, H.; et al. Xuebijing Injection Alleviates Pam3CSK4-Induced Inflammatory Response and Protects Mice from Sepsis Caused by Methicillin-Resistant *Staphylococcus aureus*. *Front. Pharmacol.* 2020, 11, 104.
23. Liu, J.; Wang, Z.; Lin, J.; Li, T.; Guo, X.; Pang, R.; Dong, L.; Duan, M. Xuebijing injection in septic rats mitigates kidney injury, reduces cortical microcirculatory disorders, and suppresses activation of local inflammation. *J. Ethnopharmacol.* 2021, 276, 114199.
24. Geng, P.; Zhang, H.; Xiong, J.; Wang, Y.; Ling, B.; Wang, H.; Tan, D.; Wang, D.; Zhang, J. XueBiJing Injection Attenuates Hydrogen Sulfide-induced Endothelial Barrier Dysfunction by Upregulating Claudin-5 Expression. *Chin. Crit. Care Med.* 2020, 32, 443–448.
25. Jiang, Y.; Zou, L.; Liu, S.; Liu, X.; Chen, F.; Liu, X.; Zhu, Y. GC/MS-based metabonomics approach reveals effects of Xuebijing injection in CLP induced septic rats. *Biomed. Pharmacother.* 2019, 117, 109163.
26. Tianyu, Z.; Liying, G. Identifying the molecular targets and mechanisms of xuebijing injection for the treatment of COVID-19 via network pharmacology and molecular docking. *Bioengineered* 2021, 12, 2274–2287.
27. Zhang, B.; Zhang, D.; Lv, J.-T.; Sa, R.-N.; Ma, B.-B.; Zhang, X.-M.; Lin, Z.-J. Molecular insight into the therapeutic promise of xuebijing injection against coronavirus disease 2019. *World J. Tradit. Chin. Med.* 2020, 6, 203–215.
28. Zuo, L.-H.; Zhou, L.; Shi, Y.-Y.; Li, Z.-L.; Liu, L.-W.; Jiang, X.-F.; Wang, D.; Yan, S.-X.; Sun, Z.; Zhang, X.-J. Mechanism of XueBiJing Injection in Anti-acute Lung Injury Based on Network Pharmacology. *Chin. Tradit. Herb. Drugs* 2018, 49, 3541–3549.
29. Feng, Y.-Y.; Xie, Y.-Y.; Wang, Y.-P.; Lian, Q.; Wang, Y.-M.; Luo, G.-A.; Wang, S.-M. Molecular Mechanism of XueBiJing Injection in Treatment of Sepsis according to Drug-target-pathway Network. *Acta Pharmaceut Sin.* 2017, 52, 556–562.
30. Sun, Z.; Zuo, L.; Sun, T.; Tang, J.; Ding, D.; Zhou, L.; Kang, J.; Zhang, X. Chemical profiling and quantification of XueBiJing injection, a systematic quality control strategy using UHPLC-Q Exactive hybrid quadrupole-orbitrap high-resolution mass spectrometry. *Sci. Rep.* 2017, 7, 1–15.
31. Li, D.; Cao, X.-X.; Pu, W.-L.; Sun, L.-L.; Ren, X.-L. Research on Quality Control Method of XueBiJing Injection. *Mod. Chin. Med.* 2018, 20, 1157–1160.
32. Zuo, L.; Sun, Z.; Hu, Y.; Sun, Y.; Xue, W.; Zhou, L.; Zhang, J.; Bao, X.; Zhu, Z.; Suo, G.; et al. Rapid determination of 30 bioactive constituents in XueBiJing injection using ultra high performance liquid chromatography-high resolution hybrid quadrupole-orbitrap mass spectrometry coupled with principal component analysis. *J. Pharm. Biomed. Anal.* 2017, 137, 220–228.

33. Huang, H.; Wang, J.; Fu, J.Z.; Wang, L.Q.; Zhao, H.Z.; Song, S.Y.; Ji, L.X.; Jiang, M.; Bai, G.; Luo, G.A. Simultaneous determination of thirteen main components and identification of eight major metabolites in Xuebijing Injection by UPLC/Q-TOF. *J. Anal. Chem.* 2013, 68, 348–356.
34. Chen, Y.; Li, Y.; Chen, X.; Wang, L.; Sun, C.; Yan, W.; Liu, X. Development and Validation of a HPLC Method for the Determination of Five Bioactive Compounds in the “Xuebijing” Injection. *Anal. Lett.* 2010, 43, 2456–2464.
35. Zhang, N.; Cheng, C.; Olaleye, O.E.; Sun, Y.; Li, L.; Huang, Y.; Du, F.; Yang, J.; Wang, F.; Shi, Y.; et al. Pharmacokinetics-Based Identification of Potential Therapeutic Phthalides from XueBiJing, a Chinese Herbal Injection Used in Sepsis Management. *Drug Metab. Dispos.* 2018, 46, 823–834.
36. Li, X.; Cheng, C.; Wang, F.; Huang, Y.; Jia, W.; Olaleye, O.; Li, M.; Li, Y.; Li, C. Pharmacokinetics of catechols in human subjects intravenously receiving XueBiJing injection, an emerging antiseptic herbal medicine. *Drug Metab. Pharmacokinet.* 2016, 31, 95–98.
37. Cheng, C.; Lin, J.-Z.; Li, L.; Yang, J.-L.; Jia, W.-W.; Huang, Y.-H.; Du, F.-F.; Wang, F.-Q.; Li, M.-J.; Li, Y.-F.; et al. Pharmacokinetics and disposition of monoterpene glycosides derived from *Paeonia lactiflora* roots (Chishao) after intravenous dosing of antiseptic XueBiJing injection in human subjects and rats. *Acta Pharmacol. Sin.* 2016, 37, 530–544.
38. Zuo, L.; Sun, Z.; Wang, Z.; Ding, D.; Xu, T.; Liu, L.; Gao, L.; Du, S.; Kang, J.; Zhang, X. Tissue distribution profiles of multiple major bioactive components in rats after intravenous administration of Xuebijing injection by UHPLC-Q-Orbitrap HRMS. *Biomed. Chromatogr.* 2019, 33, e4400.
39. Ouyang, H.-Z.; He, J. Simultaneous determination of nine constituents of Xuebijing Injection in rat plasma and their pharmacokinetics by LC-MS/MS. *China J. Chin. Mater. Med.* 2018, 43, 3553–3561.
40. Zuo, L.; Zhong, Q.; Wang, Z.; Sun, Z.; Zhou, L.; Li, Z.; Xu, T.; Shi, Y.; Tang, J.; Du, S.; et al. Simultaneous determination and pharmacokinetic study of twelve bioactive compounds in rat plasma after intravenous administration of Xuebijing injection by UHPLC-Q-Orbitrap HRMS. *J. Pharm. Biomed. Anal.* 2017, 146, 347–353.
41. Chen, X.-M.; Wang, X.-W.; Luo, J.; Jia, P.; Wang, X.-Y.; Xiao, C.-N.; Wang, S.-X.; Liu, Q.-S.; Zheng, X.-H. Pharmacokinetic Studies of XueBiJing Injection in Rats. *Chin. J. Pharm. Anal.* 2012, 32, 744–748.
42. Sheng, C.; Peng, W.; Xia, Z.; Wang, Y. Plasma and cerebrospinal fluid pharmacokinetics of hydroxysafflor yellow A in patients with traumatic brain injury after intravenous administration of Xuebijing using LC-MS/MS method. *Xenobiotica* 2019, 50, 545–551.
43. Wang, Y.; Che, J.; Zhao, H.; Tang, J.; Shi, G. Paeoniflorin attenuates oxidized low-density lipoprotein-induced apoptosis and adhesion molecule expression by autophagy enhancement in

- human umbilical vein endothelial cells. *J. Cell. Biochem.* 2019, 120, 9291–9299.
44. Xu, J.; Yang, L.; Dong, L. Tanshinol upregulates the expression of aquaporin 5 in lung tissue of rats with sepsis. *Oncol. Lett.* 2018, 16, 3290–3296.
 45. Sun, Y.; Xu, D.-P.; Qin, Z.; Wang, P.-Y.; Hu, B.-H.; Yu, J.-G.; Zhao, Y.; Cai, B.; Chen, Y.-L.; Lu, M.; et al. Protective cerebrovascular effects of hydroxysafflor yellow A (HSYA) on ischemic stroke. *Eur. J. Pharmacol.* 2018, 818, 604–609.
 46. Ji, L.; Hou, X.; Liu, W.; Deng, X.; Jiang, Z.; Huang, K.; Li, R. Paeoniflorin inhibits activation of the IRAK1-NF- κ B signaling pathway in peritoneal macrophages from lupus-prone MRL/lpr mice. *Microb. Pathog.* 2018, 124, 223–229.
 47. Bai, J.; Zhao, J.; Cui, D.; Wang, F.; Song, Y.; Cheng, L.; Gao, K.; Wang, J.; Li, L.; Li, S.; et al. Protective effect of hydroxysafflor yellow A against acute kidney injury via the TLR4/NF- κ B signaling pathway. *Sci. Rep.* 2018, 8, 1–11.
 48. Xu, X.; Guo, Y.; Zhao, J.; Wang, N.; Ding, J.; Liu, Q. Hydroxysafflor Yellow A Inhibits LPS-Induced NLRP3 Inflammasome Activation via Binding to Xanthine Oxidase in Mouse RAW264.7 Macrophages. *Mediat. Inflamm.* 2016, 2016, 1–11.
 49. Wang, L.; Liu, Z.; Dong, Z.; Pan, J.; Ma, X. Effects of Xuebijing injection on microcirculation in septic shock. *J. Surg. Res.* 2016, 202, 147–154.
 50. Hu, Y.; Duan, M.; Liang, S.; Wang, Y.; Feng, Y. Senkyunolide I protects rat brain against focal cerebral ischemia–reperfusion injury by up-regulating p-Erk1/2, Nrf2/HO-1 and inhibiting caspase 3. *Brain Res.* 2015, 1605, 39–48.
 51. Jin, M.; Sun, C.-Y.; Zang, B.-X. Hydroxysafflor yellow A attenuate lipopolysaccharide-induced endothelium inflammatory injury. *Chin. J. Integr. Med.* 2015, 22, 36–41.
 52. Wang, K.; Hu, W. Oxypaeoniflorin improves myocardial ischemia/reperfusion injury by activating the Sirt1/Foxo1 signaling pathway. *Acta Biochim. Pol.* 2020, 67, 239–245.
 53. Zhang, Q.; Zhou, J.; Huang, M.; Bi, L.; Zhou, S. Paeoniflorin Reduced BLP-Induced Inflammatory Response by Inhibiting the NF- κ B Signal Transduction in Pathway THP-1 Cells. *Cent. Eur. J. Immunol.* 2014, 39, 461–467.
 54. Li, G.; Seo, C.-S.; Lee, K.-S.; Kim, H.-J.; Chang, H.-W.; Jung, J.-S.; Song, D.-K.; Son, J.-K. Protective constituents against sepsis in mice from the root cortex of *Paeonia suffruticosa*. *Arch. Pharmacol. Res.* 2004, 27, 1123–1126.
 55. Xie, J.; Zhao, Z.-Z.; Li, P.; Zhu, C.-L.; Guo, Y.; Wang, J.; Deng, X.-M.; Wang, J.-F. Senkyunolide I Protects against Sepsis-Associated Encephalopathy by Attenuating Sleep Deprivation in a Murine Model of Cecal Ligation and Puncture. *Oxidative Med. Cell. Longev.* 2021, 2021, 1–11.

56. Su, F.; Xue, Y.; Wang, Y.; Zhang, L.; Chen, W.; Hu, S. Protective Effect of Ginsenosides Rg1 and Re on Lipopolysaccharide-Induced Sepsis by Competitive Binding to Toll-Like Receptor 4. *Antimicrob. Agents Chemother.* 2015, 59, 5654–5663.
57. Lee, W.; Ku, S.-K.; Jeong, T.C.; Lee, S.; Bae, J.-S. Ginsenosides Inhibit HMGB1-induced Inflammatory Responses in HUVECs and in Murine Polymicrobial Sepsis. *Bull. Korean Chem. Soc.* 2014, 35, 2955–2962.
58. Zou, Y.; Tao, T.; Tian, Y.; Zhu, J.; Cao, L.; Deng, X.; Li, J. Ginsenoside Rg1 improves survival in a murine model of polymicrobial sepsis by suppressing the inflammatory response and apoptosis of lymphocytes. *J. Surg. Res.* 2013, 183, 760–766.
59. Zhang, L.; Zhu, M.; Li, M.; Du, Y.; Duan, S.; Huang, Y.; Lu, Y.; Zhang, J.; Wang, T.; Fu, F. Ginsenoside Rg1 attenuates adjuvant-induced arthritis in rats via modulation of PPAR- γ /NF- κ B signal pathway. *Oncotarget* 2017, 8, 55384–55393.
60. Huang, Q.; Wang, T.; Wang, H.-Y. Ginsenoside Rb2 enhances the anti-inflammatory effect of ω -3 fatty acid in LPS-stimulated RAW264.7 macrophages by upregulating GPR120 expression. *Acta Pharmacol. Sin.* 2016, 38, 192–200.
61. Zhang, J.; Cao, L.; Wang, H.; Cheng, X.; Wang, L.; Zhu, L.; Yan, T.; Xie, Y.; Wu, Y.; Zhao, M.; et al. Ginsenosides Regulate PXR/NF- κ B Signaling and Attenuate Dextran Sulfate Sodium-Induced Colitis. *Drug Metab. Dispos.* 2015, 43, 1181–1189.
62. Sun, R.-J.; Li, Y.-N.; Chen, W.; Zhang, F.; Li, T.-S. Total Ginsenosides Synergize with Ulinastatin against Septic Acute Lung Injury and Acute Respiratory Distress Syndrome. *Int. J. Clin. Exp. Pathol.* 2015, 8, 7385–7390.
63. Zhang, Y.; Sun, K.; Liu, Y.-Y.; Zhang, Y.-P.; Hu, B.-H.; Chang, X.; Yan, L.; Pan, C.-S.; Li, Q.; Fan, J.-Y.; et al. Ginsenoside Rb1 ameliorates lipopolysaccharide-induced albumin leakage from rat mesenteric venules by intervening in both trans- and paracellular pathway. *Am. J. Physiol. Gastrointest. Liver Physiol.* 2014, 306, G289–G300.
64. Joh, E.-H.; Lee, I.-A.; Jung, I.-H.; Kim, D.-H. Ginsenoside Rb1 and its metabolite compound K inhibit IRAK-1 activation—The key step of inflammation. *Biochem. Pharmacol.* 2011, 82, 278–286.
65. Yu, T.; Yang, Y.; Kwak, Y.-S.; Song, G.G.; Kim, M.-Y.; Rhee, M.H.; Cho, J.Y. Ginsenoside Rc from *Panax ginseng* exerts anti-inflammatory activity by targeting TANK-binding kinase 1/interferon regulatory factor-3 and p38/ATF-2. *J. Ginseng Res.* 2017, 41, 127–133.
66. Jiang, R.; Dong, J.; Li, X.; Du, F.; Jia, W.; Xu, F.; Wang, F.; Yang, J.; Niu, W.; Li, C. Molecular mechanisms governing different pharmacokinetics of ginsenosides and potential for ginsenoside-perpetrated herb–drug interactions on OATP1B3. *Br. J. Pharmacol.* 2015, 172, 1059–1073.

67. Olaleye, O.; Niu, W.; Du, F.-F.; Wang, F.-Q.; Xu, F.; Pintusophon, S.; Lu, J.-L.; Yang, J.-L.; Li, C. Multiple circulating saponins from intravenous ShenMai inhibit OATP1Bs in vitro: Potential joint precipitants of drug interactions. *Acta Pharmacol. Sin.* 2019, 40, 833–849.
68. Pintusophon, S.; Niu, W.; Duan, X.-N.; Olaleye, O.E.; Huang, Y.-H.; Wang, F.-Q.; Li, Y.-F.; Yang, J.-L.; Li, C. Intravenous formulation of Panax notoginseng root extract: Human pharmacokinetics of ginsenosides and potential for perpetrating drug interactions. *Acta Pharmacol. Sin.* 2019, 40, 1351–1363.
69. You, Q.; Wang, J.; Jiang, L.; Chang, Y.; Li, W. Aqueous extract of *Aconitum carmichaelii* Debeaux attenuates sepsis-induced acute lung injury via regulation of TLR4/NF-KB pathway. *Trop. J. Pharm. Res.* 2020, 19, 533–539.
70. Tanimura, Y.; Yoshida, M.; Ishiuchi, K.; Ohsawa, M.; Makino, T. Neoline is the active ingredient of processed aconite root against murine peripheral neuropathic pain model, and its pharmacokinetics in rats. *J. Ethnopharmacol.* 2019, 241, 111859.
71. Li, Y.; Feng, Y.-F.; Liu, X.-T.; Li, Y.-C.; Zhu, H.-M.; Sun, M.-R.; Li, P.; Liu, B.; Yang, H. Songorine promotes cardiac mitochondrial biogenesis via Nrf2 induction during sepsis. *Redox Biol.* 2021, 38, 101771.
72. Ma, J.; Kan, H.; Ma, Y.; Men, L.; Pi, Z.; Liu, Z.; Liu, Z. Qualitative and quantitative analysis of drug interactions: Fritillary mediating the transport of alkaloids in caco-2 cells by p-glycoprotein. *Chem. Res. Chin. Univ.* 2014, 30, 731–737.
73. Park, J.-S.; Shin, J.A.; Jung, J.-S.; Hyun, J.-W.; Van Le, T.K.; Kim, D.-H.; Park, E.-M.; Kim, H.-S. Anti-Inflammatory Mechanism of Compound K in Activated Microglia and Its Neuroprotective Effect on Experimental Stroke in Mice. *J. Pharmacol. Exp. Ther.* 2011, 341, 59–67.
74. Yang, C.-S.; Ko, S.-R.; Cho, B.-G.; Shin, N.-M.; Yuk, J.-M.; Li, S.; Kim, J.-M.; Evans, R.M.; Jung, J.-S.; Song, N.-K.; et al. The ginsenoside metabolite compound K, a novel agonist of glucocorticoid receptor, induces tolerance to endotoxin-induced lethal shock. *J. Cell. Mol. Med.* 2008, 12, 1739–1753.
75. Zhan, T.; Yao, N.; Wu, L.; Lu, Y.; Liu, M.; Liu, F.; Xiong, Y.; Xia, C. The major effective components in Shengmai Formula interact with sodium taurocholate co-transporting polypeptide. *Phytomedicine* 2019, 59, 152916.
76. Xia, C.; Sun, J.; Wang, G.; Shang, L.; Zhang, X.; Zhang, R.; Wang, X.; Hao, H.; Xie, L. Differential effect of Shenmai injection, a herbal preparation, on the cytochrome P450 3A-mediated 1'-hydroxylation and 4-hydroxylation of midazolam. *Chem. Interact.* 2009, 180, 440–448.
77. Huang, X.; Wang, Y.; Zhang, Z.; Wang, Y.; Chen, X.; Wang, Y.; Gao, Y. Ophiopogonin D and EETs ameliorate Ang II-induced inflammatory responses via activating PPAR α in HUVECs. *Biochem. Biophys. Res. Commun.* 2017, 490, 123–133.

78. Wang, Y.; Chen, Y.; Wang, H.; Cheng, Y.; Zhao, X. Specific Turn-On Fluorescent Probe with Aggregation-Induced Emission Characteristics for SIRT1 Modulator Screening and Living-Cell Imaging. *Anal. Chem.* 2015, 87, 5046–5049.
79. Sun, Q.; Chen, L.; Gao, M.; Jiang, W.; Shao, F.; Li, J.; Wang, J.; Kou, J.; Yu, B. Ruscogenin inhibits lipopolysaccharide-induced acute lung injury in mice: Involvement of tissue factor, inducible NO synthase and nuclear factor (NF)- κ B. *Int. Immunopharmacol.* 2012, 12, 88–93.
80. Ji, X.; Ding, B.; Wu, X.; Liu, F.; Yang, F. In vitro study on the effect of ophiopogonin D on the activity of cytochrome P450 enzymes. *Xenobiotica* 2021, 51, 262–267.
81. Jiang, L.-P.; Zhao, J.; Cao, Y.-F.; Hong, M.; Sun, D.-X.; Sun, X.-Y.; Yin, J.; Zhu, Z.-T.; Fang, Z.-Z. The Inhibition of the Components from Shengmai Injection towards UDP-Glucuronosyltransferase. *Evid.-Based Complement. Altern. Med.* 2014, 2014, 1–9.
82. Liu, S.; Lu, B. Schisantherin-A Alleviates Lipopolysaccharide-Induced Inflammation and Apoptosis in WI-38 Cells. *Curr. Top. Nutraceutical Res.* 2021, 19, 421–426.
83. Bae, S.; Kim, J.; Choi, Y.; Lee, S.; Gong, J.; Choi, Y.-W.; Hwang, D. Novel Function of α -Cubebenoate Derived from Schisandra chinensis as Lipogenesis Inhibitor, Lipolysis Stimulator and Inflammasome Suppressor. *Molecules* 2020, 25, 4995.
84. Xu, J.-J.; Lu, C.-J.; Liu, Z.-J.; Zhang, P.; Guo, H.-L.; Wang, T.-T. Schizandrin B Protects LPS-Induced Sepsis via TLR4/NF- κ B/MyD88 Signaling Pathway. *Am. J. Transl. Res.* 2018, 10, 1155–1163.
85. Kook, M.; Lee, S.K.; Kim, S.D.; Lee, H.Y.; Hwang, J.S.; Choi, Y.W.; Bae, Y.-S. Anti-septic activity of α -cubebenoate isolated from Schisandra chinensis. *BMB Rep.* 2015, 48, 336–341.
86. Wang, Y.; Du, P.; Jiang, D. Berberine functions as a negative regulator in lipopolysaccharide - induced sepsis by suppressing NF- κ B and IL-6 mediated STAT3 activation. *Pathog. Dis.* 2020, 78, 47.
87. He, Y.; Yuan, X.; Zuo, H.; Sun, Y.; Feng, A. Berberine Exerts a Protective Effect on Gut-Vascular Barrier via the Modulation of the Wnt/Beta-Catenin Signaling Pathway During Sepsis. *Cell. Physiol. Biochem.* 2018, 49, 1342–1351.
88. Li, G.-X.; Wang, X.-M.; Jiang, T.; Gong, J.-F.; Niu, L.-Y.; Li, N. Berberine Prevents Intestinal Mucosal Barrier Damage During Early Phase of Sepsis in Rat through the Toll-Like Receptors Signaling Pathway. *Korean J. Physiol. Pharmacol.* 2015, 19, 1–7.
89. Gao, M.-Y.; Chen, L.; Yang, L.; Yu, X.; Kou, J.-P.; Yu, B.-Y. Berberine inhibits LPS-induced TF procoagulant activity and expression through NF- κ B/p65, Akt and MAPK pathway in THP-1 cells. *Pharmacol. Rep.* 2014, 66, 480–484.

90. Zhang, Q.; Piao, X.-L.; Lu, T.; Wang, D.; Kim, S.W. Preventive effect of *Coptis chinensis* and berberine on intestinal injury in rats challenged with lipopolysaccharides. *Food Chem. Toxicol.* 2011, 49, 61–69.
91. Kumar, A.; Ekavali, K.C.; Mukherjee, M.; Pottabathini, R.; Dhull, D.K. Current knowledge and pharmacological profile of berberine: An update. *Eur. J. Pharmacol.* 2015, 761, 288–297.
92. Lee, S.Y.; Jang, H.; Lee, J.-Y.; Ma, J.Y.; Oh, S.J.; Kim, S.K. Inhibitory effects of Hwang-Ryun-Hae-Dok-Tang on cytochrome P450 in human liver microsomes. *Xenobiotica* 2014, 45, 131–138.
93. Song, P.; Shen, D.-F.; Meng, Y.-Y.; Kong, C.-Y.; Zhang, X.; Yuan, Y.-P.; Yan, L.; Tang, Q.-Z.; Ma, Z.-G. Geniposide protects against sepsis-induced myocardial dysfunction through AMPK α -dependent pathway. *Free. Radic. Biol. Med.* 2020, 152, 186–196.
94. Liu, J.; Zhao, N.; Shi, G.; Wang, H. Geniposide ameliorated sepsis-induced acute kidney injury by activating PPAR γ . *Aging* 2020, 12, 22744–22758.
95. Cho, H.; Kim, S.; Choi, J.; Lee, S. Genipin alleviates sepsis-induced liver injury by restoring autophagy. *Br. J. Pharmacol.* 2016, 173, 980–991.
96. Liu, H.; Chen, Y.-F.; Li, F.; Zhang, H.-Y. Fructus Gardenia (*Gardenia jasminoides* J. Ellis) phytochemistry, pharmacology of cardiovascular, and safety with the perspective of new drugs development. *J. Asian Nat. Prod. Res.* 2012, 15, 94–110.
97. Yang, X.; Cai, Q.; He, J.; Chu, X.; Wei, M.; Feng, X.; Xie, X.; Huo, M.; Liu, J.; Wei, J.; et al. Geniposide, an Iridoid Glucoside Derived from *Gardenia jasminoides*, Protects against Lipopolysaccharide-induced Acute Lung Injury in Mice. *Planta Med.* 2012, 78, 557–564.
98. Zheng, X.; Yang, D.; Liu, X.; Wang, N.; Li, B.; Cao, H.; Lu, Y.; Wei, G.; Zhou, H.; Zheng, J. Identification of a new anti-LPS agent, geniposide, from *Gardenia jasminoides* Ellis, and its ability of direct binding and neutralization of lipopolysaccharide in vitro and in vivo. *Int. Immunopharmacol.* 2010, 10, 1209–1219.
99. Duan, X.-Y.; Sun, Y.; Zhao, Z.-F.; Shi, Y.-Q.; Ma, X.-Y.; Tao, L.; Liu, M.-W. Baicalin attenuates LPS-induced alveolar type II epithelial cell A549 injury by attenuation of the FSTL1 signaling pathway via increasing miR-200b-3p expression. *Innate Immun.* 2021, 27, 294–312.
100. Kuo, S.-W.; Su, W.-L.; Chou, T.-C. Baicalin improves the survival in endotoxic mice and inhibits the inflammatory responses in LPS-treated RAW 264.7 macrophages. *Eur. J. Inflamm.* 2020, 18, 18.
101. Zhu, Y.; Fu, Y.; Lin, H. Baicalin Inhibits Renal Cell Apoptosis and Protects Against Acute Kidney Injury in Pediatric Sepsis. *Med. Sci. Monit.* 2016, 22, 5109–5115.
102. Chen, H.-M.; Lou, S.-F.; Hsu, J.-H.; Chen, T.-J.; Cheng, T.-L.; Chiu, C.-C.; Yeh, J.-L. Baicalein Inhibits HMGB1 Release and MMP-2/-9 Expression in Lipopolysaccharide-induced Cardiac

Hypertrophy. *Am. J. Chin. Med.* 2014, 42, 785–797.

103. Noh, K.; Kang, Y.; Nepal, M.R.; Jeong, K.S.; Oh, D.G.; Kang, M.J.; Lee, S.; Kang, W.; Jeong, H.G.; Jeong, T.C. Role of Intestinal Microbiota in Baicalin-Induced Drug Interaction and Its Pharmacokinetics. *Molecules* 2016, 21, 337.
104. Dai, J.; Guo, W.; Tan, Y.; Niu, K.; Zhang, J.; Liu, C.; Yang, X.; Tao, K.; Chen, Z.; Dai, J. Wogonin alleviates liver injury in sepsis through Nrf2-mediated NF- κ B signalling suppression. *J. Cell. Mol. Med.* 2021, 25, 5782–5798.
105. Gao, Y.-Z.; Zhao, L.-F.; Ma, J.; Xue, W.-H.; Zhao, H. Protective mechanisms of wogonoside against Lipopolysaccharide/D-galactosamine-induced acute liver injury in mice. *Eur. J. Pharmacol.* 2016, 780, 8–15.
106. Lee, J.Y.; Park, W. Anti-Inflammatory Effect of Wogonin on RAW 264.7 Mouse Macrophages Induced with Polyinosinic-Polycytidylic Acid. *Molecules* 2015, 20, 6888–6900.
107. Zhang, L.; Ren, Y.; Yang, C.; Guo, Y.; Zhang, X.; Hou, G.; Guo, X.; Sun, N.; Liu, Y. Wogonoside Ameliorates Lipopolysaccharide-Induced Acute Lung Injury in Mice. *Inflammation* 2014, 37, 2006–2012.
108. Shao, Y.-X.; Zhao, P.; Li, Z.; Liu, M.; Liu, P.; Huang, M.; Luo, H.-B. The molecular basis for the inhibition of human cytochrome P450 1A2 by oroxylin and wogonin. *Eur. Biophys. J.* 2012, 41, 297–306.
109. Zhang, Z.; Wang, Y.; Shan, Y.; Zhou, R.; Yin, W. Oroxylin A alleviates immunoparalysis of CLP mice by degrading CHOP through interacting with FBXO15. *Sci. Rep.* 2020, 10, 1–15.
110. Tseng, T.-L.; Chen, M.-F.; Hsu, Y.-H.; Lee, T.J. OroxylinA reverses lipopolysaccharide-induced adhesion molecule expression and endothelial barrier disruption in the rat aorta. *Toxicol. Appl. Pharmacol.* 2020, 400, 115070.
111. Li, H.-F.; Wu, Y.-L.; Tseng, T.-L.; Chao, S.-W.; Lin, H.; Chen, H.-H. Inhibition of miR-155 potentially protects against lipopolysaccharide-induced acute lung injury through the IRF2BP2-NFAT1 pathway. *Am. J. Physiol. Physiol.* 2020, 319, C1070–C1081.
112. Lee, J.Y.; Park, W. Anti-inflammatory effects of oroxylin A on RAW 264.7 mouse macrophages induced with polyinosinic-polycytidylic acid. *Exp. Ther. Med.* 2016, 12, 151–156.
113. Ku, S.-K.; Han, M.-S.; Lee, M.Y.; Lee, Y.-M.; Bae, J.-S. Inhibitory effects of oroxylin A on endothelial protein C receptor shedding in vitro and in vivo. *BMB Rep.* 2014, 47, 336–341.
114. Tseng, T.-L.; Chen, M.-F.; Tsai, M.-J.; Hsu, Y.-H.; Chen, C.-P.; Lee, T.J.F. Oroxylin-A Rescues LPS-Induced Acute Lung Injury via Regulation of NF- κ B Signaling Pathway in Rodents. *PLoS ONE* 2012, 7, e47403.

115. Ren, G.; Qin, Z.; Yang, N.; Chen, H.; Fu, K.; Lu, C.; Lu, Y.; Li, N.; Zhang, Y.; Chen, X.; et al. Interactions between Oroxylin A with the solute carrier transporters and ATP-binding cassette transporters: Drug transporters profile for this flavonoid. *Chem. Interact.* 2020, 324, 109097.
116. Li, Y.; Yu, H.; Jin, Y.; Li, M.; Qu, C. Verbascoside Alleviates Atopic Dermatitis-Like Symptoms in Mice via Its Potent Anti-Inflammatory Effect. *Int. Arch. Allergy Immunol.* 2018, 175, 220–230.
117. Campo, G.; Marchesini, J.; Bristot, L.; Monti, M.; Gambetti, S.; Pavasini, R.; Pollina, A.; Ferrari, R. The in vitro effects of verbascoside on human platelet aggregation. *J. Thromb. Thrombolysis* 2012, 34, 318–325.
118. Speranza, L.; Franceschelli, S.; Pesce, M.; Reale, M.; Menghini, L.; Vinciguerra, I.; De Lutiis, M.A.; Felaco, M.; Grilli, A. Antiinflammatory effects in THP-1 cells treated with verbascoside. *Phytother. Res.* 2010, 24, 1398–1404.
119. Li, A.; Dong, L.; Duan, M.-L.; Sun, K.; Liu, Y.-Y.; Wang, M.-X.; Deng, J.-N.; Fan, J.-Y.; Wang, B.-E.; Han, J.-Y. Emodin Improves Lipopolysaccharide-Induced Microcirculatory Disturbance in Rat Mesentery. *Microcirculation* 2013, 20, 617–628.
120. Dai, S.; Ye, B.; Chen, L.; Hong, G.; Zhao, G.; Lu, Z. Emodin alleviates LPS -induced myocardial injury through inhibition of NLRP3 inflammasome activation. *Phytother. Res.* 2021, 35, 5203–5213.
121. Ding, Y.; Liu, P.; Chen, Z.-L.; Zhang, S.-J.; Wang, Y.-Q.; Cai, X.; Luo, L.; Zhou, X.; Zhao, L. Emodin Attenuates Lipopolysaccharide-Induced Acute Liver Injury via Inhibiting the TLR4 Signaling Pathway in vitro and in vivo. *Front. Pharmacol.* 2018, 9, 962.
122. Zhu, T.; Zhang, W.; Feng, S.-J.; Yu, H.-P. Emodin suppresses LPS-induced inflammation in RAW264.7 cells through a PPAR γ -dependent pathway. *Int. Immunopharmacol.* 2016, 34, 16–24.
123. Yin, J.-T.; Wan, B.; Liu, D.-D.; Wan, S.-X.; Fu, H.-Y.; Wan, Y.; Zhang, H.; Chen, Y. Emodin alleviates lung injury in rats with sepsis. *J. Surg. Res.* 2016, 202, 308–314.
124. Chen, Y.-K.; Xu, Y.-K.; Zhang, H.; Yin, J.-T.; Fan, X.; Liu, D.-D.; Fu, H.-Y.; Wan, B. Emodin alleviates jejunum injury in rats with sepsis by inhibiting inflammation response. *Biomed. Pharmacother.* 2016, 84, 1001–1007.
125. Sun, Y.-N.; Sun, L.-J.; Liu, S.-Q.; Song, J.; Cheng, J.-J.; Liu, J. Effect of Emodin on Aquaporin 5 Expression in Rats with Sepsis-Induced Acute Lung Injury. *J. Tradit. Chin. Med.* 2015, 35, 679–684.
126. Wang, D.; Wang, X.-H.; Yu, X.; Cao, F.; Cai, X.; Chen, P.; Li, M.; Feng, Y.; Li, H.; Wang, X. Pharmacokinetics of Anthraquinones from Medicinal Plants. *Front. Pharmacol.* 2021, 12, 638993.
127. Fu, S.; Zhang, J.; Gao, X.; Xia, Y.; Ferrelli, R.M.; Fauci, A.; Guerra, R.; Hu, L. Clinical practice of traditional Chinese medicines for chronic heart failure. *Hear. Asia* 2010, 2, 24–27.

128. Huang, X.; Duan, X.; Wang, K.; Wu, J.; Zhang, X. Shengmai injection as an adjunctive therapy for the treatment of chronic obstructive pulmonary disease: A systematic review and meta-analysis. *Complement. Ther. Med.* 2019, 43, 140–147.
129. Ma, D.-H.; Xi, R.; Sun, J. Adverse Reaction Characteristics and Influencing Factors of Shengmai Injections. *Pharm. Clin. Res.* 2016, 24, 324–327.
130. Ha, Y.-X.; Wang, X.-P.; Huang, P.; Zhuang, R.; Xu, X.-L.; Li, B.; Liu, Q.-Q. Effect of Shengmai Injection on Septic Shock, a Systematic Review and Meta-Analysis. *J. Emerg. Tradit. Chin. Med.* 2019, 28, 1893–1898.
131. Lu, J.; Yu, Y.; Wang, X.-J.; Chai, R.-P.; Lyu, X.-K.; Deng, M.-H.; Hu, M.-G.; Qi, Y.; Chen, X. Mechanism of Shengmai Injection on Anti-Sepsis and Protective Activities of Intestinal Mucosal Barrier in Mice. *Chin. J. Integr. Med.* 2021, 2021, 1–6.
132. Cao, Y.; Han, X.; Pan, H.; Jiang, Y.; Peng, X.; Xiao, W.; Rong, J.; Chen, F.; He, J.; Zou, L.; et al. Emerging protective roles of shengmai injection in septic cardiomyopathy in mice by inducing myocardial mitochondrial autophagy via caspase-3/Beclin-1 axis. *Inflamm. Res.* 2020, 69, 41–50.
133. Chai, R.-P.; Zhang, Y.-H.; Lu, J.; Wang, T.-J.; Chen, X. Research on Mechanism of Shengmai Injection in the Treatment of Sepsis Based on Metabolomics. *China J. Pharm. Econ.* 2019, 14, 30–34.
134. Zheng, B.-H.; Zhan, S.-Y.; Zhou, H.-Y.; Feng, Y.-H.; Fang, M.-T.; Zheng, Y.-X.; Liu, G.-Q.; Li, M.-J. Research Progress on Material Composition, Pre-clinical Pharmacokinetic and Pharmacodynamic Studies of Shengmai Injection. *Chin. Tradit. Herb. Drugs* 2020, 51, 5360–5371.
135. Zheng, C.; Hao, H.; Wang, X.; Wu, X.; Wang, G.; Sang, G.; Liang, Y.; Xie, L.; Xia, C.; Yao, X. Diagnostic fragment-ion-based extension strategy for rapid screening and identification of serial components of homologous families contained in traditional Chinese medicine prescription using high-resolution LC-ESI- IT-TOF/MS: Shengmai injection as an example. *J. Mass Spectrom.* 2008, 44, 230–244.
136. Zhao, C.; Liu, H.; Miao, P.; Wang, H.; Yu, H.; Wang, C.; Li, Z. A Strategy for Selecting "Q-Markers" of Chinese Medical Preparation via Components Transfer Process Analysis with Application to the Quality Control of Shengmai Injection. *Molecules* 2019, 24, 1811.
137. Wu, F.; Sun, H.; Wei, W.; Han, Y.; Wang, P.; Dong, T.; Yan, G.; Wang, X. Rapid and global detection and characterization of the constituents in ShengMai San by ultra-performance liquid chromatography-high-definition mass spectrometry. *J. Sep. Sci.* 2011, 34, 3194–3199.
138. Cheng, Y.-Y.; Tsai, T.-H. Analysis of Sheng-Mai-San, a Ginseng-Containing Multiple Components Traditional Chinese Herbal Medicine Using Liquid Chromatography Tandem Mass Spectrometry and Physical Examination by Electron and Light Microscopies. *Molecules* 2016, 21, 1159.

139. Zheng, Y.; Fan, C.; Liu, M.; Chen, Y.; Lu, Z.; Xu, N.; Huang, H.; Zeng, H.; Liu, S.; Cao, H.; et al. Overall quality control of the chemical and bioactive consistency of ShengMai Formula. *J. Pharm. Biomed. Anal.* 2020, 189, 113411.
140. Li, X.; Chen, H.; Jia, W.; Xie, G. A Metabolomics-Based Strategy for the Quality Control of Traditional Chinese Medicine: Shengmai Injection as a Case Study. *Evid.-Based Complement. Altern. Med.* 2013, 2013, 1–8.
141. Li, F.; Cheng, T.-F.; Dong, X.; Li, P.; Yang, H. Global analysis of chemical constituents in Shengmai injection using high performance liquid chromatography coupled with tandem mass spectrometry. *J. Pharm. Biomed. Anal.* 2016, 117, 61–72.
142. Lu, J.; Lyu, X.; Chai, R.; Yu, Y.; Deng, M.; Zhan, X.; Dong, Z.; Chen, X. Investigation of the Mechanism of Shengmai Injection on Sepsis by Network Pharmacology Approaches. *Evid.-Based Complement. Altern. Med.* 2020, 2020, 1–11.
143. Zhang, Y.; Hu, Y.; Li, M.; Wang, J.; Guo, G.; Li, F.; Yu, B.; Kou, J. The Traditional Chinese Medicine Compound, GRS, Alleviates Blood–Brain Barrier Dysfunction. *Drug Des. Dev. Ther.* 2020, 14, 933–947.
144. Zhan, S.; Shao, Q.; Fan, X.; Li, Z. Development of a sensitive LC-MS/MS method for simultaneous quantification of eleven constituents in rat serum and its application to a pharmacokinetic study of a Chinese medicine Shengmai injection. *Biomed. Chromatogr.* 2015, 29, 275–284.
145. Zhan, S.-Y.; Shao, Q.; Fan, X.-H.; Li, Z.; Cheng, Y.-Y. Tissue distribution and excretion of herbal components after intravenous administration of a Chinese medicine (Shengmai injection) in rat. *Arch. Pharmacol. Res.* 2014, 1–12.
146. Han, Y.; Sun, H.; Zhang, A.; Wu, F.; Wei, W.; Dong, T.; Wang, X. Characterization and Pharmacokinetic Study of Multiple Constituents from Shengmai San. In *Serum Pharmacokinetics of Traditional Chinese Medicine*; Wang, X., Ed.; Academic Press: Cambridge, MA, USA, 2017; pp. 103–117.
147. Han, Y.; Wu, F.; Zhang, A.; Sun, H.; Wei, W.; Wang, X. Characterization of multiple constituents in rat plasma after oral administration of Shengmai San using ultra-performance liquid chromatography coupled with electrospray ionization/quadrupole-time-of-flight high-definition mass spectrometry. *Anal. Methods* 2015, 7, 830–837.
148. Qiang, T.-T.; Li, Y.-P.; Wang, X.-L. Inhibitory Effect of Shengmai Injection on CYP450 Enzyme and Transporter in Vitro. *Chin. Tradit. Herb. Drugs* 2021, 52, 3568–3575.
149. Chiang, T.-Y.; Wang, H.-J.; Wang, Y.-C.; Tan, E.C.-H.; Lee, I.-J.; Yun, C.-H.; Ueng, Y.-F. Effects of Shengmai San on key enzymes involved in hepatic and intestinal drug metabolism in rats. *J. Ethnopharmacol.* 2021, 271, 113914.

150. Liang, Y.; Zhou, Y.; Zhang, J.; Rao, T.; Zhou, L.; Xing, R.; Wang, Q.; Fu, H.; Hao, K.; Xie, L.; et al. Pharmacokinetic Compatibility of Ginsenosides and Schisandra Lignans in Shengmai-san: From the Perspective of P-Glycoprotein. PLoS ONE 2014, 9, e98717.
-

Retrieved from <https://www.encyclopedia.pub/entry/history/show/36979>